No Data
Individual Investors Invested in Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) up 9.4% Last Week, Insiders Too Were Rewarded
Guangzhou Wondfo Biotech (300482.SZ): The respiratory triad detection product of its USA subsidiary has obtained FDA 510(k) approval.
On January 17, Gelonghui reported that Guangzhou Wondfo Biotech (300482.SZ) announced that its wholly-owned subsidiary in the USA, Wondfo USA Co., Ltd (hereinafter referred to as the "USA subsidiary"), recently received notification from the U.S. Food & Drug Administration (FDA) regarding the WELLlife COVID-19 /
Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Earnings Are Growing at Guangzhou Wondfo BiotechLtd (SZSE:300482) but Shareholders Still Don't Like Its Prospects
Guangzhou Wondfo Biotech (300482.SZ): plans to extend the "Knowledge City production base construction project" to June 2027.
On December 9th, Gelonghui reported that Guangzhou Wondfo Biotech (300482.SZ) announced that it held the seventh meeting of the fifth board of directors and the sixth meeting of the fifth board of supervisors on December 9, 2024, and reviewed and approved the "Proposal for Delaying Some Fundraising Investment Projects," agreeing to extend the time for the "Knowledge City Production Base Construction Project" to reach the predetermined usable state until June 2027, provided that there are no changes in the project implementation entity, implementation methods, use of raised funds, and investment scale. The sponsor institution issued a verification opinion, and this fundraising investment project delay is within the approval authority of the board of directors, and does not need to be submitted.
Retail Investors Are Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Biggest Owners and Were Hit After Market Cap Dropped CN¥645m
Guangzhou Wondfo BiotechLtd's (SZSE:300482) Earnings Have Declined Over Three Years, Contributing to Shareholders 56% Loss
